OP0212 Endothelin-1 induces a profibrotic phenotype in cultured human microvascular endothelial and circulating monocyte/macrophage cells

BackgroundThe alteration of microvascular endothelial cell (EC) functions and the presence of macrophages in the immune inflammatory infiltrate, followed by the transition of these cell types into a profibrotic phenotype, represent early and crucial pathological features of the fibrotic process in s...

Full description

Saved in:
Bibliographic Details
Published inAnnals of the rheumatic diseases Vol. 76; no. Suppl 2; p. 140
Main Authors Soldano, S, Montagna, P, Brizzolara, R, Trombetta, AC, Sulli, A, Pizzorni, C, Ghio, M, Paolino, S, Smith, V, Cutolo, M
Format Journal Article
LanguageEnglish
Published Kidlington Elsevier Limited 01.06.2017
Subjects
Online AccessGet full text
ISSN0003-4967
1468-2060
DOI10.1136/annrheumdis-2017-eular.4317

Cover

Loading…
Abstract BackgroundThe alteration of microvascular endothelial cell (EC) functions and the presence of macrophages in the immune inflammatory infiltrate, followed by the transition of these cell types into a profibrotic phenotype, represent early and crucial pathological features of the fibrotic process in systemic sclerosis (SSc) (1). The alternatively activated macrophage subset M2a was found in several diseases characterized by extensive fibrosis (1). M2a macrophages express specific phenotype markers, CD206 (mannose receptor), CD204 and CD163 (scavenger receptors) as well as profibrotic molecules, primarily transforming growth factor-β1 (TGFβ1) (1). Endothelin-1 (ET1) and/or TGFβ1 are known to induce the transition of fibroblasts into profibrotic myofibroblasts, which are key mediators of fibrosis in SSc.ObjectivesTo investigate the effects of ET1 in inducing a profibrotic phenotype in cultured human microvascular ECs (HMVECs) and macrophages.MethodsHMVECs, at 3rd culture passage, were grown in endothelial cell medium (EGM2MV) and treated for 6 days with ET1 (100nM) or treated for 1 hr with ET1 receptor antagonist (ETA/BRA, bosentan 10μM) before stimulation with ET1.Human monocytes were isolated from peripheral blood mononuclear cells of healthy subjects using a monocyte isolation kit. The cells were maintained in RPMI growth medium for 24 hrs and then treated for 6 days with ET1 or treated for 1 hr with bosentan before stimulation with ET1.Cultured HMVECs and monocytes maintained in EGM2MV and RPMI growth medium, respectively, were used as untreated cells. Gene and protein expression of profibrotic myofibroblast markers –α-smooth muscle actin (α-SMA), fibroblast specific protein-1 (S100A4), type 1 collagen (COL1) and fibronectin (FN) – were evaluated by quantitative real time polymerase chain reaction (qRT-PCR), Western blotting (WB) and immunocytochemistry (ICC) in cultured HMVECs. Gene and protein expression of M2a phenotype markers (CD206, CD204, CD163) and TGFβ1 were investigated by qRT-PCR and WB in cultured human macrophages. Statistical analysis was carried out by Mann-Whitney non-parametric test.ResultsIn cultured HMVECs, ET1 induced the significant upregulation of the gene expression of α-SMA, S100A4 (myofibroblast markers), COL1 and FN, compared to untreated cells (p<0.001;p<0.001;p<0.05;p<0.01). ETA/BRA significantly contrasted the ET1 mediated transition of HMVECs into a profibrotic phenotype (p<0.05 for α-SMA, COL1 and FN; p<0.01 for S100A4 vs. ET1-treated cells).In cultured human macrophages, ET1 induced the significant overexpression of M2a markers (p<0.05 for CD204 and CD163;p<0.01 for CD206) and TGFβ1 (p<0.01) compared to untreated cells. ETA/BRA significantly contrasted the ET1-mediated transition of cultured macrophages into profibrotic M2a (p<0.05 vs. ET1-treated cells, for all investigated proteins). Data were confirmed by WB and ICC on both cultured cell types.ConclusionsET1 seems to be involved in the early phases of the fibrotic process by inducing the transition of both cultured HMVECs and macrophages into a profibrotic phenotype, myofibroblast and M2a respectively (observed in SSc), a process which is apparently contrasted by ETA/BRA treatment.References Wynn TA et al. Immunity. 2016;44:450–62. Disclosure of InterestS. Soldano: None declared, P. Montagna: None declared, R. Brizzolara: None declared, A. Trombetta: None declared, A. Sulli: None declared, C. Pizzorni: None declared, M. Ghio: None declared, S. Paolino: None declared, V. Smith: None declared, M. Cutolo Grant/research support from: Actelion
AbstractList BackgroundThe alteration of microvascular endothelial cell (EC) functions and the presence of macrophages in the immune inflammatory infiltrate, followed by the transition of these cell types into a profibrotic phenotype, represent early and crucial pathological features of the fibrotic process in systemic sclerosis (SSc) (1). The alternatively activated macrophage subset M2a was found in several diseases characterized by extensive fibrosis (1). M2a macrophages express specific phenotype markers, CD206 (mannose receptor), CD204 and CD163 (scavenger receptors) as well as profibrotic molecules, primarily transforming growth factor-β1 (TGFβ1) (1). Endothelin-1 (ET1) and/or TGFβ1 are known to induce the transition of fibroblasts into profibrotic myofibroblasts, which are key mediators of fibrosis in SSc.ObjectivesTo investigate the effects of ET1 in inducing a profibrotic phenotype in cultured human microvascular ECs (HMVECs) and macrophages.MethodsHMVECs, at 3rd culture passage, were grown in endothelial cell medium (EGM2MV) and treated for 6 days with ET1 (100nM) or treated for 1 hr with ET1 receptor antagonist (ETA/BRA, bosentan 10μM) before stimulation with ET1.Human monocytes were isolated from peripheral blood mononuclear cells of healthy subjects using a monocyte isolation kit. The cells were maintained in RPMI growth medium for 24 hrs and then treated for 6 days with ET1 or treated for 1 hr with bosentan before stimulation with ET1.Cultured HMVECs and monocytes maintained in EGM2MV and RPMI growth medium, respectively, were used as untreated cells. Gene and protein expression of profibrotic myofibroblast markers –α-smooth muscle actin (α-SMA), fibroblast specific protein-1 (S100A4), type 1 collagen (COL1) and fibronectin (FN) – were evaluated by quantitative real time polymerase chain reaction (qRT-PCR), Western blotting (WB) and immunocytochemistry (ICC) in cultured HMVECs. Gene and protein expression of M2a phenotype markers (CD206, CD204, CD163) and TGFβ1 were investigated by qRT-PCR and WB in cultured human macrophages. Statistical analysis was carried out by Mann-Whitney non-parametric test.ResultsIn cultured HMVECs, ET1 induced the significant upregulation of the gene expression of α-SMA, S100A4 (myofibroblast markers), COL1 and FN, compared to untreated cells (p<0.001;p<0.001;p<0.05;p<0.01). ETA/BRA significantly contrasted the ET1 mediated transition of HMVECs into a profibrotic phenotype (p<0.05 for α-SMA, COL1 and FN; p<0.01 for S100A4 vs. ET1-treated cells).In cultured human macrophages, ET1 induced the significant overexpression of M2a markers (p<0.05 for CD204 and CD163;p<0.01 for CD206) and TGFβ1 (p<0.01) compared to untreated cells. ETA/BRA significantly contrasted the ET1-mediated transition of cultured macrophages into profibrotic M2a (p<0.05 vs. ET1-treated cells, for all investigated proteins). Data were confirmed by WB and ICC on both cultured cell types.ConclusionsET1 seems to be involved in the early phases of the fibrotic process by inducing the transition of both cultured HMVECs and macrophages into a profibrotic phenotype, myofibroblast and M2a respectively (observed in SSc), a process which is apparently contrasted by ETA/BRA treatment.ReferencesWynn TA et al. Immunity. 2016;44:450–62.Disclosure of InterestS. Soldano: None declared, P. Montagna: None declared, R. Brizzolara: None declared, A. Trombetta: None declared, A. Sulli: None declared, C. Pizzorni: None declared, M. Ghio: None declared, S. Paolino: None declared, V. Smith: None declared, M. Cutolo Grant/research support from: Actelion
BackgroundThe alteration of microvascular endothelial cell (EC) functions and the presence of macrophages in the immune inflammatory infiltrate, followed by the transition of these cell types into a profibrotic phenotype, represent early and crucial pathological features of the fibrotic process in systemic sclerosis (SSc) (1). The alternatively activated macrophage subset M2a was found in several diseases characterized by extensive fibrosis (1). M2a macrophages express specific phenotype markers, CD206 (mannose receptor), CD204 and CD163 (scavenger receptors) as well as profibrotic molecules, primarily transforming growth factor-β1 (TGFβ1) (1). Endothelin-1 (ET1) and/or TGFβ1 are known to induce the transition of fibroblasts into profibrotic myofibroblasts, which are key mediators of fibrosis in SSc.ObjectivesTo investigate the effects of ET1 in inducing a profibrotic phenotype in cultured human microvascular ECs (HMVECs) and macrophages.MethodsHMVECs, at 3rd culture passage, were grown in endothelial cell medium (EGM2MV) and treated for 6 days with ET1 (100nM) or treated for 1 hr with ET1 receptor antagonist (ETA/BRA, bosentan 10μM) before stimulation with ET1.Human monocytes were isolated from peripheral blood mononuclear cells of healthy subjects using a monocyte isolation kit. The cells were maintained in RPMI growth medium for 24 hrs and then treated for 6 days with ET1 or treated for 1 hr with bosentan before stimulation with ET1.Cultured HMVECs and monocytes maintained in EGM2MV and RPMI growth medium, respectively, were used as untreated cells. Gene and protein expression of profibrotic myofibroblast markers –α-smooth muscle actin (α-SMA), fibroblast specific protein-1 (S100A4), type 1 collagen (COL1) and fibronectin (FN) – were evaluated by quantitative real time polymerase chain reaction (qRT-PCR), Western blotting (WB) and immunocytochemistry (ICC) in cultured HMVECs. Gene and protein expression of M2a phenotype markers (CD206, CD204, CD163) and TGFβ1 were investigated by qRT-PCR and WB in cultured human macrophages. Statistical analysis was carried out by Mann-Whitney non-parametric test.ResultsIn cultured HMVECs, ET1 induced the significant upregulation of the gene expression of α-SMA, S100A4 (myofibroblast markers), COL1 and FN, compared to untreated cells (p<0.001;p<0.001;p<0.05;p<0.01). ETA/BRA significantly contrasted the ET1 mediated transition of HMVECs into a profibrotic phenotype (p<0.05 for α-SMA, COL1 and FN; p<0.01 for S100A4 vs. ET1-treated cells).In cultured human macrophages, ET1 induced the significant overexpression of M2a markers (p<0.05 for CD204 and CD163;p<0.01 for CD206) and TGFβ1 (p<0.01) compared to untreated cells. ETA/BRA significantly contrasted the ET1-mediated transition of cultured macrophages into profibrotic M2a (p<0.05 vs. ET1-treated cells, for all investigated proteins). Data were confirmed by WB and ICC on both cultured cell types.ConclusionsET1 seems to be involved in the early phases of the fibrotic process by inducing the transition of both cultured HMVECs and macrophages into a profibrotic phenotype, myofibroblast and M2a respectively (observed in SSc), a process which is apparently contrasted by ETA/BRA treatment.References Wynn TA et al. Immunity. 2016;44:450–62. Disclosure of InterestS. Soldano: None declared, P. Montagna: None declared, R. Brizzolara: None declared, A. Trombetta: None declared, A. Sulli: None declared, C. Pizzorni: None declared, M. Ghio: None declared, S. Paolino: None declared, V. Smith: None declared, M. Cutolo Grant/research support from: Actelion
Background The alteration of microvascular endothelial cell (EC) functions and the presence of macrophages in the immune inflammatory infiltrate, followed by the transition of these cell types into a profibrotic phenotype, represent early and crucial pathological features of the fibrotic process in systemic sclerosis (SSc) (1). The alternatively activated macrophage subset M2a was found in several diseases characterized by extensive fibrosis (1). M2a macrophages express specific phenotype markers, CD206 (mannose receptor), CD204 and CD163 (scavenger receptors) as well as profibrotic molecules, primarily transforming growth factor-β1 (TGFβ1) (1). Endothelin-1 (ET1) and/or TGFβ1 are known to induce the transition of fibroblasts into profibrotic myofibroblasts, which are key mediators of fibrosis in SSc. Objectives To investigate the effects of ET1 in inducing a profibrotic phenotype in cultured human microvascular ECs (HMVECs) and macrophages. Methods HMVECs, at 3rd culture passage, were grown in endothelial cell medium (EGM2MV) and treated for 6 days with ET1 (100nM) or treated for 1 hr with ET1 receptor antagonist (ETA/BRA, bosentan 10μM) before stimulation with ET1. Human monocytes were isolated from peripheral blood mononuclear cells of healthy subjects using a monocyte isolation kit. The cells were maintained in RPMI growth medium for 24 hrs and then treated for 6 days with ET1 or treated for 1 hr with bosentan before stimulation with ET1. Cultured HMVECs and monocytes maintained in EGM2MV and RPMI growth medium, respectively, were used as untreated cells. Gene and protein expression of profibrotic myofibroblast markers -α-smooth muscle actin (α-SMA), fibroblast specific protein-1 (S100A4), type 1 collagen (COL1) and fibronectin (FN) - were evaluated by quantitative real time polymerase chain reaction (qRT-PCR), Western blotting (WB) and immunocytochemistry (ICC) in cultured HMVECs. Gene and protein expression of M2a phenotype markers (CD206, CD204, CD163) and TGFβ1 were investigated by qRT-PCR and WB in cultured human macrophages. Statistical analysis was carried out by Mann-Whitney non-parametric test. Results In cultured HMVECs, ET1 induced the significant upregulation of the gene expression of α-SMA, S100A4 (myofibroblast markers), COL1 and FN, compared to untreated cells (p<0.001;p<0.001;p<0.05;p<0.01). ETA/BRA significantly contrasted the ET1 mediated transition of HMVECs into a profibrotic phenotype (p<0.05 for α-SMA, COL1 and FN; p<0.01 for S100A4 vs. ET1-treated cells). In cultured human macrophages, ET1 induced the significant overexpression of M2a markers (p<0.05 for CD204 and CD163;p<0.01 for CD206) and TGFβ1 (p<0.01) compared to untreated cells. ETA/BRA significantly contrasted the ET1-mediated transition of cultured macrophages into profibrotic M2a (p<0.05 vs. ET1-treated cells, for all investigated proteins). Data were confirmed by WB and ICC on both cultured cell types. Conclusions ET1 seems to be involved in the early phases of the fibrotic process by inducing the transition of both cultured HMVECs and macrophages into a profibrotic phenotype, myofibroblast and M2a respectively (observed in SSc), a process which is apparently contrasted by ETA/BRA treatment. ReferencesWynn TA et al. Immunity. 2016;44:450-62. Disclosure of Interest S. Soldano: None declared, P. Montagna: None declared, R. Brizzolara: None declared, A. Trombetta: None declared, A. Sulli: None declared, C. Pizzorni: None declared, M. Ghio: None declared, S. Paolino: None declared, V. Smith: None declared, M. Cutolo Grant/research support from: Actelion
Author Soldano, S
Paolino, S
Pizzorni, C
Montagna, P
Smith, V
Trombetta, AC
Cutolo, M
Brizzolara, R
Sulli, A
Ghio, M
Author_xml – sequence: 1
  givenname: S
  surname: Soldano
  fullname: Soldano, S
  organization: Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genoa, Genoa, Italy
– sequence: 2
  givenname: P
  surname: Montagna
  fullname: Montagna, P
  organization: Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genoa, Genoa, Italy
– sequence: 3
  givenname: R
  surname: Brizzolara
  fullname: Brizzolara, R
  organization: Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genoa, Genoa, Italy
– sequence: 4
  givenname: AC
  surname: Trombetta
  fullname: Trombetta, AC
  organization: Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genoa, Genoa, Italy
– sequence: 5
  givenname: A
  surname: Sulli
  fullname: Sulli, A
  organization: Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genoa, Genoa, Italy
– sequence: 6
  givenname: C
  surname: Pizzorni
  fullname: Pizzorni, C
  organization: Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genoa, Genoa, Italy
– sequence: 7
  givenname: M
  surname: Ghio
  fullname: Ghio, M
  organization: Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genoa, Genoa, Italy
– sequence: 8
  givenname: S
  surname: Paolino
  fullname: Paolino, S
  organization: Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genoa, Genoa, Italy
– sequence: 9
  givenname: V
  surname: Smith
  fullname: Smith, V
  organization: Department of Rheumatology, Ghent University Hospital, Ghent, Belgium
– sequence: 10
  givenname: M
  surname: Cutolo
  fullname: Cutolo, M
  organization: Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genoa, Genoa, Italy
BookMark eNqVkc1q3TAQhUVJoTdp30GQtZORpSvZdBVC-gOBZNGuhf4c62JLjmQH7i6brvKWeZLKuQ10Fchq0Mw5Mzp8x-goxOAQOiVwRgjl5yqE1LtltD5XNRBRuWVQ6YxRIj6gDWG8KW0OR2gDALRiLRef0HHOu_KEhjQb9HRzCzWpnx__XAUb594NPlQE-2AX4zJWeEqx8zrF2Rs89S7EeT-5MsdmGeYlOYv7ZVQBj96k-KCyWX-A3esyNWAVLDY-rYPZhzs8xhDNfnbnoyqWqVd3Dhs3DPkz-tipIbsv_-oJ-v3t6tflj-r65vvPy4vrStfQiIoQEHoLgjfUAmdcG1bC2baxNelqJTTYljKqGrBW846K1oqOardted1pQ-kJOj3sLdnuF5dnuYtLCuWkrBkjrKW02b6pgqJot_Ci-npQlSg5J9fJKflRpb0kIFdG8j9GcmUkXxjJlVFx84Nbj7t3Gf8CLTqhpw
ContentType Journal Article
Copyright 2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions
Copyright: 2017 © 2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions
2017 2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions
Copyright_xml – notice: 2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions
– notice: Copyright: 2017 © 2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions
– notice: 2017 2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions
DBID AAYXX
CITATION
3V.
7X7
7XB
88E
88I
8AF
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
BTHHO
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9-
K9.
LK8
M0R
M0S
M1P
M2P
M7P
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
Q9U
DOI 10.1136/annrheumdis-2017-eular.4317
DatabaseName CrossRef
ProQuest Central (Corporate)
ProQuest Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Science Database (Alumni Edition)
STEM Database
ProQuest SciTech Collection
ProQuest Natural Science Collection
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Database (Proquest)
ProQuest Central
Natural Science Collection
BMJ Journals
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
Consumer Health Database
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
Consumer Health Database
ProQuest Health & Medical Collection
Medical Database
Science Database
Biological Science Database
ProQuest Central Premium
ProQuest One Academic
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
DatabaseTitle CrossRef
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest AP Science
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Family Health (Alumni Edition)
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Science Journals (Alumni Edition)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest Science Journals
ProQuest Family Health
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
BMJ Journals
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
DatabaseTitleList ProQuest Central Student

ProQuest Central Student
Database_xml – sequence: 1
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1468-2060
EndPage 140
ExternalDocumentID 10_1136_annrheumdis_2017_eular_4317
annrheumdis
GroupedDBID ---
.55
.GJ
.VT
169
23M
2WC
39C
3O-
4.4
40O
53G
5GY
5RE
5VS
6J9
7X7
7~S
88E
88I
8AF
8FE
8FH
8FI
8FJ
8R4
8R5
AAHLL
AAKAS
AAOJX
AAWJN
AAWTL
AAXUO
ABAAH
ABJNI
ABKDF
ABMQD
ABOCM
ABTFR
ABUWG
ABVAJ
ACGFO
ACGFS
ACGOD
ACGTL
ACHTP
ACMFJ
ACOAB
ACOFX
ACPRK
ACQSR
ACTZY
ADBBV
ADCEG
ADFRT
ADUGQ
ADZCM
AEKJL
AENEX
AFKRA
AFWFF
AGQPQ
AHMBA
AHNKE
AHQMW
AJYBZ
AKKEP
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ASPBG
AVWKF
AZFZN
AZQEC
BAWUL
BBNVY
BENPR
BHPHI
BKNYI
BLJBA
BOMFT
BPHCQ
BTFSW
BTHHO
BVXVI
C1A
C45
CAG
CCPQU
COF
CS3
CXRWF
DIK
DWQXO
E3Z
EBS
EJD
F5P
FDB
FYUFA
GNUQQ
H13
HAJ
HCIFZ
HMCUK
HYE
HZ~
IAO
IEA
IHR
INH
INR
IOF
ITC
J5H
K9-
KQ8
L7B
LK8
M0R
M1P
M2P
M7P
N9A
NTWIH
NXWIF
O9-
OK1
OVD
P2P
PHGZT
PQQKQ
PROAC
PSQYO
Q2X
R53
RHI
RMJ
RPM
RV8
RWL
RXW
TAE
TEORI
TR2
UAW
UKHRP
UYXKK
V24
VM9
VVN
W2D
W8F
WH7
WOQ
X6Y
X7M
YFH
YOC
YQY
ZGI
ZXP
AAFWJ
AALRI
AAYXX
CITATION
PHGZM
3V.
7XB
8FK
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQUKI
PRINS
Q9U
ID FETCH-LOGICAL-b2087-1107b507683d0646bc4003d98d21f2a7b0d9343a80ddb6f379d7f3be5962fbc33
IEDL.DBID 7X7
ISSN 0003-4967
IngestDate Fri Jul 25 11:04:13 EDT 2025
Fri Jul 25 11:06:28 EDT 2025
Tue Jul 01 00:58:34 EDT 2025
Thu Apr 24 22:50:27 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue Suppl 2
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-b2087-1107b507683d0646bc4003d98d21f2a7b0d9343a80ddb6f379d7f3be5962fbc33
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
OpenAccessLink https://ard.bmj.com/content/annrheumdis/76/Suppl_2/140.2.full.pdf
PQID 2033895085
PQPubID 2041045
PageCount 1
ParticipantIDs proquest_journals_2441493385
proquest_journals_2033895085
crossref_primary_10_1136_annrheumdis_2017_eular_4317
bmj_primary_10_1136_annrheumdis_2017_eular_4317
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20170600
2017-06-00
20170601
PublicationDateYYYYMMDD 2017-06-01
PublicationDate_xml – month: 06
  year: 2017
  text: 20170600
PublicationDecade 2010
PublicationPlace Kidlington
PublicationPlace_xml – name: Kidlington
PublicationTitle Annals of the rheumatic diseases
PublicationYear 2017
Publisher Elsevier Limited
Publisher_xml – name: Elsevier Limited
SSID ssj0000818
Score 2.2156694
Snippet BackgroundThe alteration of microvascular endothelial cell (EC) functions and the presence of macrophages in the immune inflammatory infiltrate, followed by...
Background The alteration of microvascular endothelial cell (EC) functions and the presence of macrophages in the immune inflammatory infiltrate, followed by...
SourceID proquest
crossref
bmj
SourceType Aggregation Database
Index Database
Publisher
StartPage 140
SubjectTerms Actin
Caregivers
CD163 antigen
Cell culture
Collagen
Comorbidity
Councils
Culture media
Endothelial cells
Endothelin 1
Endothelins
Fibroblasts
Fibronectin
Fibrosis
Gene expression
Genotype & phenotype
Immunocytochemistry
Inflammation
Investigations
Leukocytes (mononuclear)
Macrophages
Mannose
Mental depression
Microvasculature
Monocytes
Peripheral blood mononuclear cells
Phenotypes
Polymerase chain reaction
Protein expression
Proteins
Rheumatoid arthritis
Rheumatology
S100A4 protein
Scleroderma
Sclerosis
Smooth muscle
Statistical analysis
Transforming growth factor-b1
Western blotting
Title OP0212 Endothelin-1 induces a profibrotic phenotype in cultured human microvascular endothelial and circulating monocyte/macrophage cells
URI https://ard.bmj.com/content/76/Suppl_2/140.2.full
https://www.proquest.com/docview/2033895085
https://www.proquest.com/docview/2441493385
Volume 76
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1JSwMxFA7aQvEirrhUCeh17JJkZnISlZYitBax0NuQrS7QGe1y8ObFk__SX-J76YxSEMFzZoF8L2_Le-8j5DSWwoBbqwLFdRTwWPJAGTcKpDSiblykBMN-524v7Az49VAM84TbNC-rLHSiV9Q2M5gjr4EZAmceAipx_vwSIGsU3q7mFBqrpIyjyzD4iobRjyaOG3HBmMdlGFXISc5igiQvkwc3H9vHKQgKaGqHVZ9naE7Byujx07KdWlbT3va0N8h67jTSiwXKm2TFpVuk0s2vxbfJx00fZ6h_vr23UostVeA7Bg0K4TYAN6WKemZuPcngfYpFXRlmXmGdLgZvOEs9Vx8dY3leUZxKXfEx-LdKLTWPE-PZvtJ7CtuRmdeZq40VkoA9gFqieAkw3SGDduvuqhPkLAuBbtZBw2AAqAVeyDEL_kmoDRxrZmVsm41RU0W6biXjTMV1iy17LJI2GjHtkLZnpA1ju6SUZqnbI9QKCOZibnUsJDc61IC4CSWz1jaFE3yf1GBnk-fFHI3Exx_M90QXWCSIReKxSBCLfcILFP73WrVALMnPJD4D0oOkt-L35W8BO_h7-ZCseYnxqZgqKc0mc3cEnslMH3vxOybly1avf_sFE0znyQ
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1NTxRBEK0QTNCLET8iitCJchx3drp7ZvpgjBHIIix4gGRvQ38tLMnOrLtLDDcunPwv_ih_iVW90xoSY8KBc0_PJF1v6lV1V_UDeFcqaTGs1YkWpkhEqUSirR8mSlmZWl9oyanfuX-Y907El4EcLMHP2AtDZZXRJwZH7RpLe-QdpCEM5jGhkh8n3xJSjaLT1SihsYDFvr_6jinb7MPeNtp3K8t2d44_95JWVSAxWYp_FCU8RtIBFHfIx7mxCGPuVOmy7jDThUmd4oLrMnXUosYL5YohN55kaobG0gYouvwHSLwplRAWg-Kv5y-7ZVToEyovVuBtq5pCojLTc385dqMZAhOZwVOV6Xuib2Q1M764zYu3aSFw3e4TeNwGqezTAlWrsOTrp7DSb4_hn8GPo690Z_uv65ud2lELF8aqSZdheo9AmTHNghK4mTY4n1ERWUM7vTjOFhd9eMeCNiAbUzlgLIZlPr4Mv61rx-xoaoO6WH3GcPkbezX3nbEm0bFzdIOMDh1mz-HkXtb_BSzXTe1fAnMSk8dSOFNKJazJDSLM5oo75zLppViDDq5sNVnc21GFfIeHHuxoi4psUQVbVGSLNRDRCnebth4tVrU-gJ5BtJLIrvz38B9Av_r_8CY87B33D6qDvcP91_AooCdsA63D8nx66d9gVDQ3GwGKDE7vG_u_AbHPIY8
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LaxRBEC5ChMWLaFRMjKZBPY67O909PX0QEZMlDxNzMLC3sV-TB-xM3N0guXnJKf_In-Mvsap3WgmIkEPOPQ_o-rq-qu6q_gBel1o6DGtNZoRVmSi1yIwLdaa1kwMXlJGc-p33D4rtI7E7luMl-Jl6YaisMvnE6Kh962iPvI80hME8JlSyX3dlEYebo_fn3zJSkKKT1iSnsYDIXrj8junb7N3OJtr6TZ6Ptr583M46hYHM5gNcXZT8WEmHUdwjNxfWIaS516XPh3VulB14zQU35cBTuxpX2qua20CSNbV1tBmK7v-e4kibuJbUWP1lgXJYJrU-oQvVg1edggoJzExPwsXEn84QpMgSgSpO3xKVI8PZydlNjrxJEZH3Rg_hQRewsg8LhD2CpdCsQG-_O5J_DNefD-n-9l8_rrYaT-1cGLdmQ4apPoJmxgyLquB22uL7jArKWtr1xXG2uPQjeBZ1AtmESgNTYSwL6WP4b9N45k6nLiqNNccMp791l_PQnxgSIDtBl8joAGL2BI7uZP6fwnLTNuEZMC8xkSyFt6XUwtnCItpcobn3PpdBilXo48xW54s7PKqY-_DYj51sUZEtqmiLimyxCiJZ4XavrSeLVZ0_oGcQuSS4K_89_Afca_8f3oAeor76tHOw9xzuR_DEHaF1WJ5PL8ILDJDm9mVEIoOvdw393-WaJcU
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=OP0212%E2%80%85Endothelin-1+induces+a+profibrotic+phenotype+in+cultured+human+microvascular+endothelial+and+circulating+monocyte%2Fmacrophage+cells&rft.jtitle=Annals+of+the+rheumatic+diseases&rft.au=Soldano%2C+S&rft.au=Montagna%2C+P&rft.au=Brizzolara%2C+R&rft.au=Trombetta%2C+A+C&rft.date=2017-06-01&rft.pub=Elsevier+Limited&rft.issn=0003-4967&rft.eissn=1468-2060&rft.volume=76&rft.spage=140&rft.epage=140&rft_id=info:doi/10.1136%2Fannrheumdis-2017-eular.4317&rft.externalDBID=HAS_PDF_LINK
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0003-4967&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0003-4967&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0003-4967&client=summon